Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317396727> ?p ?o ?g. }
- W4317396727 endingPage "55" @default.
- W4317396727 startingPage "39" @default.
- W4317396727 abstract "Background: Drugs having high first-pass metabolism or that are susceptible to enzymatic degradation can be administered through the nasal route to avoid their degradation. Lurasidone exhibits less toxicity and side effects as compared to its sister drugs like risperidone, ziprasidone, clozapine, etc. Objectives: The present study aimed to develop Lurasidone loaded niosomes for nasal delivery. Methods: Lurasidone niosomes were developed by adapting the ether injection method and optimized using a central composite design. In vitro and in vivo studies were conducted using optimized formulation. Results: The findings showed that the optimized formulation exhibited a particle size of 159.02 ± 0.58 nm and an entrapment efficiency of 91.6 ± 1.6%. The findings from the nasal histopathological analysis revealed that the optimized formulation was non-irritant and non-toxic for nasal mucosa. The findings from in vitro studies revealed 94.61 ± 0.27% of drug release from optimized formulation F7 throughout 24 hrs. The findings of in vivo (Albino Wistar rats) studies demonstrated that various pharmacokinetic parameters (Cmax, Tmax, AUC(0-24), T1/2, Vd and Cl) and pharmcodynamic parameters (conditioned avoidance response, biochemical estimation using oxidative markers such as superoxide dismutase, malondialdehyde and glutathione) were significantly improved compared to marketed tablets (Lurasid® 40 mg) and pure drug suspension. Optimized formulation F-7 exhibited 4.9 times more bioavailability than that of pure drug suspension following intranasal administration. Conclusion: These findings indicate that nasal niosomal formulation of Lurasidone HCl is a promising nanoplatform for enhancing the overall performance of Lurasidone. These results could open new avenues into the future of nanomedicine." @default.
- W4317396727 created "2023-01-19" @default.
- W4317396727 creator A5001208539 @default.
- W4317396727 creator A5006064109 @default.
- W4317396727 creator A5041623180 @default.
- W4317396727 creator A5045837608 @default.
- W4317396727 creator A5074462144 @default.
- W4317396727 creator A5080588119 @default.
- W4317396727 date "2023-03-01" @default.
- W4317396727 modified "2023-09-30" @default.
- W4317396727 title "Engineering of Lurasidone Hydrochloride Loaded Niosomes for Enhancing the Antipsychotic Potential for Nasal Administration" @default.
- W4317396727 cites W1988652094 @default.
- W4317396727 cites W1999166183 @default.
- W4317396727 cites W2001496295 @default.
- W4317396727 cites W2028080874 @default.
- W4317396727 cites W2032941040 @default.
- W4317396727 cites W2043326331 @default.
- W4317396727 cites W2053892140 @default.
- W4317396727 cites W2068846148 @default.
- W4317396727 cites W2100557888 @default.
- W4317396727 cites W2103510658 @default.
- W4317396727 cites W2119023371 @default.
- W4317396727 cites W2137017984 @default.
- W4317396727 cites W2399638512 @default.
- W4317396727 cites W2753400916 @default.
- W4317396727 cites W2782690276 @default.
- W4317396727 cites W2793549224 @default.
- W4317396727 cites W2914096421 @default.
- W4317396727 cites W2915567917 @default.
- W4317396727 cites W2922248411 @default.
- W4317396727 cites W2967691925 @default.
- W4317396727 cites W2988264264 @default.
- W4317396727 cites W3010327875 @default.
- W4317396727 cites W3022244097 @default.
- W4317396727 cites W3025029304 @default.
- W4317396727 cites W3092861403 @default.
- W4317396727 cites W3105839859 @default.
- W4317396727 cites W3128182165 @default.
- W4317396727 cites W3159063483 @default.
- W4317396727 cites W3162431417 @default.
- W4317396727 cites W3165600411 @default.
- W4317396727 cites W3172578915 @default.
- W4317396727 cites W3176114961 @default.
- W4317396727 cites W3178394812 @default.
- W4317396727 cites W4288926751 @default.
- W4317396727 doi "https://doi.org/10.2174/2468187313666230117163425" @default.
- W4317396727 hasPublicationYear "2023" @default.
- W4317396727 type Work @default.
- W4317396727 citedByCount "0" @default.
- W4317396727 crossrefType "journal-article" @default.
- W4317396727 hasAuthorship W4317396727A5001208539 @default.
- W4317396727 hasAuthorship W4317396727A5006064109 @default.
- W4317396727 hasAuthorship W4317396727A5041623180 @default.
- W4317396727 hasAuthorship W4317396727A5045837608 @default.
- W4317396727 hasAuthorship W4317396727A5074462144 @default.
- W4317396727 hasAuthorship W4317396727A5080588119 @default.
- W4317396727 hasConcept C118552586 @default.
- W4317396727 hasConcept C130316041 @default.
- W4317396727 hasConcept C150903083 @default.
- W4317396727 hasConcept C181389837 @default.
- W4317396727 hasConcept C185592680 @default.
- W4317396727 hasConcept C201253974 @default.
- W4317396727 hasConcept C207001950 @default.
- W4317396727 hasConcept C22979827 @default.
- W4317396727 hasConcept C2776151105 @default.
- W4317396727 hasConcept C2776412080 @default.
- W4317396727 hasConcept C2776701107 @default.
- W4317396727 hasConcept C2778401633 @default.
- W4317396727 hasConcept C2780494398 @default.
- W4317396727 hasConcept C41625074 @default.
- W4317396727 hasConcept C55493867 @default.
- W4317396727 hasConcept C71924100 @default.
- W4317396727 hasConcept C72918618 @default.
- W4317396727 hasConcept C85663871 @default.
- W4317396727 hasConcept C86803240 @default.
- W4317396727 hasConcept C98274493 @default.
- W4317396727 hasConceptScore W4317396727C118552586 @default.
- W4317396727 hasConceptScore W4317396727C130316041 @default.
- W4317396727 hasConceptScore W4317396727C150903083 @default.
- W4317396727 hasConceptScore W4317396727C181389837 @default.
- W4317396727 hasConceptScore W4317396727C185592680 @default.
- W4317396727 hasConceptScore W4317396727C201253974 @default.
- W4317396727 hasConceptScore W4317396727C207001950 @default.
- W4317396727 hasConceptScore W4317396727C22979827 @default.
- W4317396727 hasConceptScore W4317396727C2776151105 @default.
- W4317396727 hasConceptScore W4317396727C2776412080 @default.
- W4317396727 hasConceptScore W4317396727C2776701107 @default.
- W4317396727 hasConceptScore W4317396727C2778401633 @default.
- W4317396727 hasConceptScore W4317396727C2780494398 @default.
- W4317396727 hasConceptScore W4317396727C41625074 @default.
- W4317396727 hasConceptScore W4317396727C55493867 @default.
- W4317396727 hasConceptScore W4317396727C71924100 @default.
- W4317396727 hasConceptScore W4317396727C72918618 @default.
- W4317396727 hasConceptScore W4317396727C85663871 @default.
- W4317396727 hasConceptScore W4317396727C86803240 @default.
- W4317396727 hasConceptScore W4317396727C98274493 @default.
- W4317396727 hasIssue "1" @default.
- W4317396727 hasLocation W43173967271 @default.